Analyst Price Targets — DYN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 12:23 pm | — | Evercore ISI | $33.00 | $17.79 | TheFly | Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI |
| May 13, 2026 10:28 am | — | Bernstein | $24.00 | $18.37 | TheFly | Dyne Therapeutics price target raised to $24 from $23 at Bernstein |
| March 2, 2026 10:37 pm | Keay Nakae | Chardan Capital | $38.00 | $16.15 | StreetInsider | Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN) |
| March 2, 2026 4:12 pm | Michael E Ulz | Morgan Stanley | $47.00 | $15.68 | StreetInsider | Dyne Therapeutics (DYN) PT Lowered to $47 at Morgan Stanley |
| December 15, 2025 1:38 pm | Gavin Clark-Gartner | Evercore ISI | $36.00 | $19.51 | TheFly | Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI |
| December 11, 2025 12:22 pm | — | Stifel Nicolaus | $39.00 | $19.69 | TheFly | Dyne Therapeutics price target raised to $39 from $36 at Stifel |
| December 10, 2025 11:49 am | — | Oppenheimer | $40.00 | $18.44 | TheFly | Dyne Therapeutics upgraded to Outperform from Perform at Oppenheimer |
| December 9, 2025 12:40 pm | William Pickering | Tudor Pickering | $23.00 | $19.09 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group |
| December 9, 2025 11:49 am | — | Bernstein | $23.00 | $22.20 | TheFly | Dyne Therapeutics price target raised to $23 from $21 at Bernstein |
| December 8, 2025 5:06 pm | Michael E Ulz | Morgan Stanley | $50.00 | $22.20 | StreetInsider | Dyne Therapeutics (DYN) PT Raised to $50 at Morgan Stanley |
Latest News for DYN
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerate drug discovery across several therapeutic areas.
Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis while expanding its reach into gene editing and pain management.
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more than three decades of biopharmaceutical industry experience and a track record of building and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DYN.
U.S. House Trading
No House trades found for DYN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.